Clinical trial · Observational
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
Identification of New Biomarkers for Patients With Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) - do They Provide New Information Regarding Diagnosis, Treatment Efficacy, Side Effects, or Prognosis?
NCT05184400CI-TRIAL-00055902CHOCArecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
No validated biomarkers exist that can identify patients with biliary tract cancer at an early stage or predict treatment outcomes. The objective of the present study is to find diagnostic, prognostic and predictive biomarkers.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Cancer | Malignant Biliary Tract Neoplasm | ALIAS | 0.90 |
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Gallbladder Cancer | Malignant Gallbladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Diagnostic accuracy (sensitivity and specificity)
- timeFrame
- Baseline
- description
- Outcome for diagnostic biomarkers. Case-control design.
- measure
- Overall survival (OS)
- timeFrame
- Baseline to death or lost to follow-up, an average of 1 year
- description
- Outcome for prognostic and predictive biomarkers
Secondary outcomes (2)
- measure
- Progression free survival (PFS)
- timeFrame
- Baseline to progression, death or lost to follow-up, an average of 1 year
- description
- Outcome for prognostic and predictive biomarkers
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological diagnosis of BTC * Patients referred for treatment of BTC * Signed informed consent Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.